Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety of the triple COG schema with the monoclonal
antibody Dinutuximab + cytokines (GM-CSF and IL2) and isotretinoin (13-cis-retinoic acid, or
RA) in patients with high-risk neuroblastoma.